In Vivo Vulnerability to Competition by Endogenous Dopamine: Comparison of the D2 Receptor Agonist Radiotracer (-)-N-[ 11C]propyl-norapomorphine ([11C]NPA) with the D 2 Receptor Antagonist Radiotracer [11C]-Raclopride

Synapse

Volumn 52, Issue 3, 2004, Pages 188-208

  Narendran, Rajesh ^a,b   Hwang, Dah Ren ^a   Slifstein, Mark ^a   Talbot, Peter S ^a   Erritzoe, David ^a   Huang, Yiyun ^a   Cooper, Thomas B ^a   Martinez, Diana ^a   Kegeles, Lawrence S ^a   Abi Dargham, Anissa ^a   Laruelle, Marc ^a  

^a New York State Psychiatric Institute ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

11C NPA; 11C raclopride; Agonist; Amphetamine; Antagonist; Dopamine; PET

Indexed keywords

AMPHETAMINE; CARBON 11; DOPAMINE; PROPYLNORAPOMORPHINE; RACLOPRIDE; TRACER;

ANIMAL EXPERIMENT; ARTICLE; BABOON; BINDING AFFINITY; COMPETITION; DOSE RESPONSE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KINETICS; MALE; MASS SPECTROMETRY; NONHUMAN; PARTITION COEFFICIENT; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ALGORITHMS; AMPHETAMINE; ANIMALS; APOMORPHINE; BINDING, COMPETITIVE; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; PAPIO; RACLOPRIDE; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 2342595176     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.20013     Document Type: Article

References (85)

1. Abi-Dargham A, Laruelle M, Seibyl J, Rattner Z, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Bremner JD, Hyde TM, Charney DS, Hoffer PB, Innis RB. 1994. SPECT measurement of benzodiazepine receptors in human brain with [123-I]iomazenil: kinetic and equilibrium paradigms. J Nucl Med 35:228-238.
2. Abi-Dargham A, Gil R, Krystal J, Baldwin R, Seibyl J, Bowers M, van Dyck C, Charney D, Innis R, Laruelle M. 1998. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761-767.
3. 11C]NNC 756. Synapse 32:93-109.
4. 2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97:8104-8109.
5. Anand A, Verhoeff P, Seneca N, Zoghbi SS, Seibyl JP, Charney DS, Innis RB. 2000. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry 157:1108-1114.
6. 3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain. Eur J Pharmacol 146:113-120.
7. Andersen PH, Nielsen EB. 1986. The benzazepine, SCH 23390, inhibits 3H-NPA binding in mouse brain in vivo. Acta Pharmacol Toxicol 59:315-318.
8. Argiolas A, Mereu G, Serra G, Melis MR, Fadda F, Gessa GL. 1982. N-n-propyl-norapomorphine: an extremely potent stimulant of dopamine autoreceptors. Brain Res 231:109-116.
9. 2-selective dopamine agonist. Neuropharmacology 30:97-99.
10. Baldessarini RJ, Kula NS, Zong R, Neumeyer JL. 1994. Receptor affinities of aporphine enantiomers in rat brain tissue. Eur J Pharmacol 254:199-203.
11. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, deBartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D. 1997. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94:2569-2574.
12. Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H, Haberkorn U, Doll J, Oberdorfer F, Lorenz WJ. 1997. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med 38: 1614-1623.
13. Carson RE, Breier A, deBartolomeis A, Saunders RC, Su TP, Schmall B, Der MG, Pickar D, Eckelman WC. 1997. Quantification of amphetamine-induced changes in [C-11]raclopride binding with continuous infusion. J Cereb Blood Flow Metab 17:437-447.
14. Cotzias GC, Papavasiliou PS, Ginos JZ. 1976. Therapeutic approaches in Parkinson's disease: possible roles of growth hormone and somatostatin. Res Publ Assoc Res Nerv Ment Dis 55:305-315.
15. Cumming P, Wong DF, Dannals RF, Gillings N, Hilton J, Scheffel U, Gjedde A. 2002a. The competition between endogenous dopamine and radioligands for specific binding to dopamine receptors. Ann NY Acad Sci 965:440-450.
16. Cumming P, Wong DF, Gillings N, Hilton J, Scheffel U, Gjedde A. 2002b. Specific binding of [(11)C]raclopride and N-[(3)H]propyl-norapomorphine to dopamine receptors in living mouse striatum: occupancy by endogenous dopamine and guanosine triphosphate-free G protein. J Cereb Blood Flow Metab 22:596-604.
17. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13:350-356.
18. Drevets WC, Price JC, Kupfer DJ, Kinahan PE, Lopresti B, Holt D, Mathis C. 1999. PET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum. Neuropsychopharmacology 21:694-709.
19. Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA, Price JL, Mathis CA. 2001. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 49:81-96.
20. Endres CJ, Kolachana BS, Saunders RC, Su T, Weinberger D, Breier A, Eckelman WC, Carson RE. 1997. Kinetic modeling of [C-11]raclopride: combined PET-microdialysis studies. J Cereb Blood Flow Metab 17:932-942.
21. Gandelman MS, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Innis RB. 1994. Evaluation of ultrafiltration for the free fraction determination of single photon emission computerized tomography (SPECT) radiotracers: β-CIT, IBF and iomazenil. J Pharmaceutical Sci 83: 1014-1019.
22. 2(long) dopamine receptors: ligand binding and functional assays. Br J Pharmacol 124:978-984.
23. George SR, Watanabe M, Di Paolo T, Falardeau P, Labrie F, Seeman P. 1985a. The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology 117: 690-697.
24. 2 receptors in the anterior pituitary: a single population without reciprocal antagonist/agonist states. J Neurochem 44:1168-1177.
25. Ginovart N, Farde L, Halldin C, Swahn CG. 1997. Effect of reserpine-induced depletion of synaptic dopamine on [C-11]raclopride binding to D-2-dopamine receptors in the monkey brain. Synapse 25:321-325.
26. Goldman ME, Kebabian JW. 1984. Aporphine enantiomers. Interactions with D-1 and D-2 dopamine receptors. Mol Pharmacol 25:18-23.
27. 2 dopamine receptors from the high- to the low-affinity state for dopamine agonists, using sodium ions and guanine nucleotide. J Neurochem 44:1925-1935.
28. Gulat-Marnay C, Lafitte A, Schwartz JC, Protais P. 1985. Effects of discriminant and non-discriminant dopamine antagonists on in vivo accumulation of 3H-N-propyl-norapomorphine in mouse striatum and tuberculum olfactorium. Naunyn Schmied Arch Pharmacol 329:117-122.
29. 2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 11: 245-256.
30. 2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J Neurosci 15:5222-5237.
31. Hwang D, Kegeles LS, Laruelle M. 2000. (-)-N-[(11)C]propyl-norapomorphine: a positron-labeled dopamine agonist for PET imaging of D(2) receptors. Nucl Med Biol 27:533-539.
32. 11C]NPA) in vivo binding in nonhuman primates. J Nucl Med 45:338-346.
33. 2 receptor in non-human primates. Synapse 10:177-184.
34. 123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans. Synapse 31:302-308.
35. 3H]N-propylnorapomorphine in the mouse brain. Evidence for labelling of central dopamine receptors. Eur J Pharmacol 72:397-402.
36. Kohler C, Hall H, Ogren SO, Gawell L. 1985. Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 34:2251-2259.
37. Lahti RA, Mutin A, Cochrane EV, Tepper PG, Dijkstra D, Wikstrom H, Tamminga CA. 1996. Affinities and intrinsic activities of dopamine receptor agonists for the hD21 and hD4.4 receptors. Eur J Pharmacol 301:R11-13.
38. Laruelle M. 2000. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423-451.
39. 2 receptors in healthy subjects. J Nucl Med 35:743-754.
40. Laruelle M, Wallace E, Seibyl JP, Baldwin RM, Zea-Ponce Y, Zoghbi SS, Neumeyer JL, Charney DS, Hoffer PB, Innis RB. 1994b. Graphical, kinetic and equilibrium analysis of [123-I]β-CIT in vivo binding to dopamine transporters in healthy subjects. J Cereb Blood Flow Metab 14:982-994.
41. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF, Innis RB. 1995. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36:1182-1190.
42. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, De Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. 1996. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects. Proc Natl Acad Sci USA 93:9235-9240.
43. Laruelle M, Iyer RN, Al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, Baldwin RM, Kung HF, Charney DS, Hoffer PB, Innis RB, Bradberry CW. 1997. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25:1-14.
44. Laruelle M, Abi-Dargham A, Innis RB. 1998. Imaging receptor occupancy by endogenous transmitters in humans. In: Carson R, Daube-Whiterspoon ME, Herscovith P, editors. Quantitative functional brain imaging with positron emission tomography. San Diego: Academic Press.
45. Levenberg K. 1944. A method for the solution of certain problems in least squares. Q Appl Math 2:164-168.
46. 2 dopamine receptors in brain with subtype-specific antibodies. Proc Natl Acad Sci USA 90:8861-8865.
47. Martin LP, Cox RF, Waszczak BL. 1990. Efficacy and potency comparisons among aporphine enantiomers: effects on dopamine neurons in substantia nigra of rat. Neuropharmacology 29:135-143.
48. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, Cooper T, Kegeles L, Zarahn E, Abi-Dargham A, Haber SN, Laruelle M. 2003. Imaging human mesolimbic dopamine transmission with positron emission tomography. II. Amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 23:285-300.
49. 2 receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 21:1034-1057.
50. Menon MK, Clark WG, Neumeyer JL. 1978. Comparison of the dopaminergic effects of apomorphine and (-)-N-n-propylnorapomorphine. Eur J Pharmacol 52:1-9.
51. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. 1984. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15:217-227.
52. Mouradian MM, Heuser IJ, Baronti F, Giuffra M, Conant K, Davis TL, Chase TN. 1991. Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry 54:401-405.
53. Neumeyer JL, Neustadt BR, Oh KH, Weinhardt KK, Boyce CB, Rosenberg FJ, Teiger DG. 1973. Aporphines. 8. Total synthesis and pharmacological evaluation of (plus or minus)-apomorphine, (plus or minus)-apocodeine, (plus or minus)-N-n-propylnorapomorphine, and (plus or minus)-N-n-propylnorapocodeine. J Med Chem 16: 1223-1228.
54. Parsey RV, Oquendo MA, Zea-Ponce Y, Rodenhiser J, Kegeles LS, Pratap M, Cooper TB, Van Heertum R, Mann JJ, Laruelle M. 2001. Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry 50:313-322.
55. Piccini P, Pavese N, Brooks DJ. 2003. Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann Neurol 53:647-653.
56. Price J, Mason NS, Lopresti B, Holt D, Simpson NR, Drevets W, Smith GS, Mathis CA. 1998. PET measurement of endogenous neurotransmitter activity using high and low affinity radiotracers. In: Carson R, Daube-Witherspoon ME, Herscovitch P, editors. Quantitative functional brain imaging with positron emission tomography. San Diego: Academic Press. p 441-448.
57. Reimer ML, Mamer OA, Zavitsanos AP, Siddiqui AW, Dadgar D. 1993. Determination of amphetamine, methamphetamine and desmethyldeprenyl in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. Biol Mass Spectrom 22:235-242.
58. Riche D, Hantraye P, Guibert B, Naquet R, Loch'h C, Mazière M. 1988. Anatomical atlas of the baboon's brain in the orbito-meatal plane used in experimental positron emission tomography. Brain Res Bull 20:283-301.
59. 2 dopamine receptor autoradiography: high percentage of high-affinity agonist sites and increased nucleotide sensitivity in tissue sections. Brain Res 383:121-128.
60. 2 receptors in the rat central nervous system. Neuroscience 30:767-777.
61. 2 receptors in the rat central nervous system. Neuroscience 30:767-777.
62. Rinken A, Finnman UB, Fuxe K. 1999. Pharmacological characterization of dopamine-stimulated [35S]-guanosine 5′(gamma-thiotriphosphate) ([35S]GTPgammaS) binding in rat striatal membranes. Biochem Pharmacol 57:155-162.
63. 3H](-)-N-n-propylnorapomorphine in the mouse brain. Naunyn Schmied Arch Pharmacol 340:13-20.
64. Rowland M, Tozer TN. 1989. Clinical pharmacokinetics. Philadelphia: Lea & Febiger.
65. Schoenfeld RI, Neumeyer JL, Dafeldecker W, Roffier-Tarlov S. 1975. Comparison of structural and stereoisomers of apomorphine on stereotyped behavior of the rat. Eur J Pharmacol 30:63-68.
66. Seeman P. 1993. Receptor Tables. Vol. 2: drug dissociation constants for neuroreceptors and transporters. Toronto: Schizophrenia Research.
67. Seeman P, Grigoriadis D. 1987. Dopamine receptors in brain and periphery. Neurochem Int 10:1-25.
68. 2 receptor binding sites for agonists. A tetrahedral model. Mol Pharmacol 28:391-399.
69. 2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc Natl Acad Sci USA 86:10156-10160.
70. Seeman P, Sunahara RK, Niznik HB. 1994. Receptor-receptor link in membranes revealed by ligand competition-example for dopamine D-1 and D-2 receptors. Synapse 17:62-64.
71. 2 dopamine receptor. J Biol Chem 257:6351-6361.
72. Singer HS, Szymanski S, Giuliano J, Yokoi F, Dogan AS, Brasic JR, Zhou Y, Grace AA, Wong DF. 2002. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am J Psychiatry 159:1329-1336.
73. Slifstein M, Parsey RV, Laruelle M. 2000. Derivation of [(11)C] WAY-100635 binding parameters with reference tissue models: effect of violations of model assumptions. Nucl Med Biol 27:487-492.
74. Sunahara RK, Guan HC, O'Dowd BF, Seeman P, Laurier LG, Ng G, George SR, Torchia J, Van Tol HH, Niznik HB. 1991. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 350:614-619.
75. Tamminga CA, Gotts MD, Thaker GK, Alphs LD, Foster NL. 1986. Dopamine agonist treatment of schizophrenia with N-propyl-norapomorphine. Arch Gen Psychiatry 43:398-402.
76. Tiberi M, Jarvie KR, Silvia C, Falardeau P, Gingrich JA, Godinot N, Bertrand L, Yang-Feng TL, Fremeau Jr R, Caron MG. 1991. Cloning, molecular characterization, and chromosomal assignment of a gene encoding a second D1 dopamine receptor subtype: differential expression pattern in rat brain compared with the D1A receptor. Proc Natl Acad Sci USA 88:7491-7495.
77. 11C]raclopride? PET studies combined with microdialysis in conscious monkeys. Brain Res 841:160-169.
78. van der Werf JF, Sebens JB, Vaalburg W, Korf J. 1983. In vivo binding of N-n-propylnorapomorphine in the rat brain: regional localization, quantification in striatum and lack of correlation with dopamine metabolism. Eur J Pharmacol 87:259-270.
79. Verhoeff NP, Hussey D, Lee M, Tauscher J, Papatheodorou G, Wilson AA, Houle S, Kapur S. 2002. Dopamine depletion results in increased neostriatal D(2), but not D(1), receptor binding in humans. Mol Psychiatry 7:233-238.
80. Villemagne VL, Wong DF, Yokoi F, Stephane M, Rice KC, Matecka D, Clough DJ, Dannals RF, Rothman RB. 1999. GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [(11)C]raclopride continuous infusion PET scans. Synapse 33:268-273.
81. Woods RP, Mazziotta JC, Cherry SR. 1993. MRI-PET registration with automated algorithm. J Comput Assist Tomogr 17:536-546.
82. Yarbrough GG, McGuffin-Clineschmidt J, Singh DK, Haubrich DR, Bendesky RJ, Martin GE. 1984. Electrophysiological, biochemical and behavioral assessment of dopamine autoreceptor activation by a series of dopamine agonists. Eur J Pharmacol 99:73-78.
83. 2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience 65:709-730.
84. Zahniser NR, Molinoff PB. 1978. Effect of guanine nucleotides on striatal dopamine receptors. Nature 275:453-455.
85. Zhang X, Segawa T. 1989. Selective blockade of dopamine D-1 receptor by SCH 23390 affects dopamine agonist binding to 3H-spiperone labeled D-2 receptors in rat striatum. Jpn J Pharmacol 50:333-345.